These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9817540)

  • 1. Multiple sclerosis clinical trials: old and new challenges.
    Noseworthy JH
    Semin Neurol; 1998; 18(3):377-88. PubMed ID: 9817540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS
    Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving therapies for multiple sclerosis.
    Korniychuk E; Dempster JM; O'Connor E; Alexander JS; Kelley RE; Kenner M; Menon U; Misra V; Hoque R; Gonzalez-Toledo E; Schwendimann RN; Smith S; Minagar A
    Int Rev Neurobiol; 2007; 79():571-88. PubMed ID: 17531859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological problems in evaluating efficacy of a treatment in multiple sclerosis.
    Waubant E; Goodkin D
    Pathol Biol (Paris); 2000 Mar; 48(2):104-13. PubMed ID: 10815286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial.
    Lappin MS; Lawrie FW; Richards TL; Kramer ED
    Altern Ther Health Med; 2003; 9(4):38-48. PubMed ID: 12868251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.
    Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P
    Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G; Coustans M
    Pathol Biol (Paris); 2000 Mar; 48(2):114-20. PubMed ID: 10815287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.